Handelsbanken Fonder
IGMS

Handelsbanken Fonder’s IGM Biosciences IGMS Stock Holding History

Handelsbanken Fonder’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,900
Closed -$241K – 1684
2021
Q2 		$241K Buy
+2,900
New +$215K ﹤0.01% 1674

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Handelsbanken Fonder's IGMS Position: Q3 2021 in Review

Handelsbanken Fonder sold out of IGM Biosciences (IGMS) in Q3 2021, closing a stake of 2,900 shares — an estimated $241K sold.

Handelsbanken Fonder first reported a position in IGMS in Q2 2021 and held it in 1 quarter. The position peaked at $241K in Q2 2021. 107 funds tracked by Wall St. Rank hold IGMS as of Q3 2021.

  • Handelsbanken Fonder reported no remaining IGM Biosciences position as of Q3 2021 after selling out during the quarter.
  • Handelsbanken Fonder sold 2,900 IGM Biosciences shares in Q3 2021, an estimated $241K.
  • Handelsbanken Fonder first reported a position in IGM Biosciences in Q2 2021 and held it in 1 quarter.
  • Handelsbanken Fonder's IGM Biosciences position peaked at $241K in Q2 2021.
  • 107 funds tracked by Wall St. Rank held IGM Biosciences as of Q3 2021.

Based on Handelsbanken Fonder's 13F filing for Q3 2021, filed 10 Nov 2021.